“…In the absence of a clinical response, ESS is undertaken with an estimated 450, 000 cases performed annually in the United States alone (Meltzer et al, 2004). In addition to restoring mucociliary drainage pathways for the paranasal sinuses, ESS optimizes CRS disease control by optimizing sinonasal mucosal distribution of topical therapies (Harvey et al, 2008(Harvey et al, , 2010Abouali et al, 2012;Snidvongs et al, 2013;Thomas 3rd et al, 2013;Bahmanzadeh et al, 2015;Wofford et al, 2015;Barham et al, 2016;Zhao et al, 2016). Impaired olfaction is a frequent complaint among patients afflicted with CRS, with a reported incidence of up to 80% in these patients (Raviv and Kern, 2004;Rosenfeld et al, 2007;Jiang et al, 2008;Soler et al, 2008;Litvack et al, 2009b).…”